Study of MGD013 in Patients with Unresectable or Metastatic Neoplasms

• Research type

  Research Study

• Full title

  A Phase I, First-in-Human, Open-Label, Dose Escalation Study of MGD013, a Bispecific DART(R) Protein binding PD-1 and LAG-3 in Patients with Unresectable or Metastatic Neoplasms

• IRAS ID

  256720

• Contact name

  Fiona Thistlethwaite

• Contact email

  fiona.thistlethwaite@christie.nhs.uk

• Sponsor organisation

  Macrogenics Inc.

• Eudract number

  2018-003153-21

• Clinicaltrials.gov Identifier

  NCT03219268

• Duration of Study in the UK

  1 years, 9 months, 30 days

• Research summary

  This is an open-label, Phase 1 study to investigate the safety, tolerability and effective dose of MGD013 when given intravenously every 2 weeks to patients with unresectable or metastatic cancers. “Open label” means that both patient and study doctor know what study medication is being administered. All patients in this study will receive the study medication MGD013. In this study, MGD013 will be given intravenously every 2 weeks to patients.

• REC name

  HSC REC B

• REC reference

  19/NI/0028

• Date of REC Opinion

  2 Apr 2019

• REC opinion

  Further Information Favourable Opinion